Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
06:13pm, Thursday, 22'nd Dec 2022 Benzinga
Gainers
Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
IsoPlexis Corporation (NA
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
02:15pm, Tuesday, 20'th Dec 2022 GlobeNewswire Inc.
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following
Is Anavex Life Sciences a Buy?
02:45pm, Tuesday, 13'th Dec 2022 The Motley Fool
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
12:45am, Thursday, 08'th Dec 2022 Benzinga
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds. The Nasdaq and the S&P 500 closed marginally in
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
04:40pm, Wednesday, 07'th Dec 2022
The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
02:15pm, Tuesday, 06'th Dec 2022 GlobeNewswire Inc.
AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
05:30pm, Tuesday, 22'nd Nov 2022 GlobeNewswire Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s
Cassava Sciences Stock's Bull Signal Has Never Been Wrong
02:51pm, Monday, 21'st Nov 2022
The shares of Cassava Sciences Inc (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
06:30pm, Friday, 18'th Nov 2022 GlobeNewswire Inc.
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
10:43am, Wednesday, 16'th Nov 2022
High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more com
Cassava Sciences stock pops after rival experiences setback in Alzheimer's research
04:40pm, Monday, 14'th Nov 2022
Yahoo Finance anchors Rachelle Akuffo, Seana Smith and Dave Briggs shares of Cassava moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.
Why Is Cassava Sciences (SAVA) Stock Up Today?
02:38pm, Monday, 14'th Nov 2022
In today's mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon's session is Cassava Sciences (NASDAQ: SAVA ).
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
02:00pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 –
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
12:13pm, Monday, 07'th Nov 2022
Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company's third-quarter earnings and a stark warning to short sellers. During Q3, the company reported a net loss of
Short sellers hit back at Cassava lawsuit against them: ‘We stand behind everything we wrote’
03:17pm, Friday, 04'th Nov 2022 MarketWatch
The defendants at the heart of a lawsuit from meme stock Cassava have hit back at the plaintiff, saying it’s one of the most “frivolous” lawsuits they’ve seen
